MORF News and Press, Morphic Holding Inc. From 09/22/23

2023-09-22 15:27:43 ET More on Morphic Seeking Alpha’s Quant Rating on Morphic Historical earnings data for Morphic Financial information for Morphic Morphic: High Valuation Not Justified By Data, Development Status, Or Cash Stifel cuts Morphic...

2023-09-22 12:52:13 ET For further details see: CETX, MYO and MORF among mid-day movers

WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Marc Schegerin, MD, COO & CFO, will participate in a...

2023-08-09 18:43:54 ET Stifel has downgraded Morphic ( NASDAQ: MORF ) to hold, stating that it believes open-label data for its anti-inflammatory drug candidate MORF-057 isn't enough to score a near-term M&A deal. Stifel said that while the immunology and inflammation space ...

WALTHAM, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Offic...

2023-08-03 10:36:34 ET Morphic press release ( NASDAQ: MORF ): Q2 GAAP EPS of -$0.92. Revenue was $0 million for the quarter ended June 30, 2023, compared to $60.2 million for the same quarter last year due to the conclusion of the Company’s research and development...

-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater than $730 million in cash and equivalents at 6/30/23; extended cash runway into seco...

Morphic Holding, Inc. (NASDAQ: MORF) is the focus of IBN's latest stock spotlight. The company's shares have moved 2.07% on the day to $60.15. Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, c...

2023-07-10 15:12:02 ET Summary Morphic Holding, Inc. is progressing with its trials nicely enough. I just have a problem with the nearly $3bn valuation for this phase 2 stage company. Nothing they have done or said justifies it. Morphic Holding ( MORF ) devel...

WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the Jefferies He...